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Background: Advanced melanoma patients have an extremely poor long term prognosis and are in strong need
of new therapies. The recently developed targeted therapies have resulted in a marked antitumor effect, but most
responses are partial and some degree of toxicity remain the major concerns.
Dendritic cells play a key role in the activation of the immune system and have been typically used as ex vivo
antigen-loaded cell drugs for cancer immunotherapy.
Another approach consists in intratumoral injection of unloaded DCs that can exploit the uptake of a wider array of
tumor-specific and individual unique antigens. However, intratumoral immunization requires DCs endowed at the
same time with properties typically belonging to both immature and mature DCs (i.e. antigen uptake and T cell
priming). DCs generated in presence of interferon-alpha (IFN-DCs), due to their features of partially mature DCs,
capable of efficiently up-taking, processing and cross-presenting antigens to T cells, could successfully carry out this
task. Combining intratumoral immunization with tumor-destructing therapies can induce antigen release in situ,
facilitating the injected DCs in triggering an antitumor immune response.
Methods: We tested in a phase I clinical study in advanced melanoma a chemo-immunotherapy approach based
on unloaded IFN-DCs injected intratumorally one day after administration of dacarbazine. Primary endpoint of the
study was treatment safety and tolerability. Secondary endpoints were immune and clinical responses of patients.
Results: Six patients were enrolled, and only three completed the treatment. The chemo-immunotherapy was well
tolerated with no major side effects. Three patients showed temporary disease stabilization and two of them
showed induction of T cells specific for tyrosinase, NY-ESO-1 and gp100. Of interest, one patient showing a
remarkable long-term disease stabilization kept showing presence of tyrosinase specific T cells in PBMC and
high infiltration of memory T cells in the tumor lesion at 21 months.
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Conclusion: We tested a chemo-immunotherapeutic approach based on IFN-DCs injected intratumorally one
day after DTIC in advanced melanoma. The treatment was well tolerated, and clinical and immunological
responses, including development of vitiligo, were observed, therefore warranting additional clinical studies
aimed at evaluating efficacy of this approach.
Trial registration: Trial Registration Number not publicly available due to EudraCT regulations: https://
www.clinicaltrialsregister.eu/doc/EU_CTR_FAQ.pdf
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The outcome of patients with advanced melanoma re-
mains bleak. Patients with stage IV disease have poor
long term prognosis, with 50-70% surviving less than
one year and with 5-year survival rates of approxi-
mately 10% [1]. Before 2011, in the pre anti-BRAF/
anti-CTLA4 and, more recently, anti-PD1 era, the
reference chemotherapeutic agent for the treatment of
metastatic melanoma was Dacarbazine (DTIC) with an
activity in term of overall response rates (ORR) ranging
from 5% to 12% [2]. However, complete responses were
observed in less than 5% of patients, the most of them
being not durable [3]. Analogous conclusion can be
drawn with cytokine-based therapies (i.e. IFN-α or IL-2)
or combined chemo-biotherapies which, although im-
proved the response rate in the range of 15-20%, did not
result in increased overall survival [3,4]. Recently, targeted
therapies based on the use of selective inhibitors of MAPK
pathway enzymes in patients showing activating mutations
have resulted in a marked antitumor effect, but most
responses are partial and disease progression is typically
seen at a median of 5–7 months [5]. Notably, immuno-
therapy has recently re-emerged has a powerful approach
for the treatment of advanced melanoma as a result of the
registration of a novel type of monoclonal antibodies
(ipilimumab, anti-CTLA4; pembrolizumab, anti-PD1) tar-
geting the immune checkpoints [6]. However, while such
therapy can result in a significant improvement of survival
rate in the range of 22% at 3 years, [7,8] the lack of
response in the majority of patients and some degree of
toxicity remain the major concerns.
DCs represent the professional cells involved in the
induction and regulation of immune response and, during
the past years, DC-based immunotherapy has emerged as
a promising approach for treating cancer [9]. However,
the results of several clinical studies carried out in cancer
patients, and in particular in melanoma patients, have also
highlighted many critical aspects (type of antigen, DC gen-
eration method and maturation status, use of adjuvant,
route of vaccine administration, vaccine- induced immune
response, combination with conventional therapies)
whose definition is of utmost importance in order to
enhance the efficacy of DC-based treatment [10].Notably, DC-based trials have been generally per-
formed by using monocyte-derived DCs generated
in vitro in the present of IL-4 and GM-CSF and further
treated with different types of stimulation factors [11].
IFN-α has been proven to induce the rapid differenti-
ation of GM-CSF-treated human monocytes into partially
mature DCs (IFN-DCs) [12-14] endowed with potent
functional activities [12,15,16]. IFN-DCs produce mostly
T-helper-1 (Th-1) cytokines and chemokines, express toll-
like receptors (TLRs) 1 to 8, show migratory response to
chemokines, and are capable of stimulating Th-1 polarized
immune responses after injection into severe combined
immunodeficient mice reconstituted with human periph-
eral blood leukocytes [14,15]. Notably, IFN-DCs exert a
direct cytotoxic effect on tumor cells, [12] are capable
to take up, through the scavenger receptor Lectin-like
oxidized-LDL receptor-1 (LOX-1), apoptotic cells [17]
and cross-present their antigens to CD8+ T cells, thus
leading to an efficient cross-priming of these cells
[18-20]. In addition, IFN-DCs are capable of expanding
both Th-1 and Th-17 responses as a result of the
production of cytokines such as IL-23 and IL-12 [21].
Remarkably, IFN-DCs do not require TLR triggering to
induce antigen specific cytotoxic T lymphocytes and to
stimulate allogeneic CD4+ T cells [22]. All these features
make IFN-DCs highly promising new candidates for the
development of more effective DC-based strategies of
cancer immunotherapy [23,24].
For typical active immunotherapy strategies, DCs are
generated ex vivo from monocytes, pulsed with tumor
antigens, and then injected into patients. Another ap-
proach consists in intratumoral injection of unloaded
DCs, which has been tested in experimental models
[25,26] as well as in humans [27,28]. This approach
can exploit the uptake by the DCs of a wide array of
tumor-derived antigens, including tumor-specific and
individual unique antigens, and their DC-mediated
presentation to the immune system, possibly resulting
in the redirecting of tumor-specific responses back to the
tumor site. However, the intratumoral immunization re-
quires DCs endowed at the same time with properties typ-
ically belonging to both immature and mature DCs (i.e.
antigen uptake and T cell priming), unless immature
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co-delivered with a maturation stimuli necessary for ef-
fective T cell activation. IFN-DCs, due to their features
of partially mature DCs, capable of efficiently up-taking,
processing and cross-presenting antigens to T cells, can
successfully carry out this task [24].
Combining intratumoral immunization with tumor-
destructing therapies can induce antigen release in situ, fa-
cilitating the injected DCs in triggering an antigen-driven
immune response [29]. Indeed, intratumoral DC-based
immunotherapy has been used in combination with sys-
temically administered antitumor drugs [30-34] as well as
locally targeted therapies such as radiation therapy [35-40]
on the basis of recent evidence indicating that both cyto-
toxic drugs and radiation induce a form of tumor cell
death that is immunologically active, therefore facilitating
an adaptive immune response [41]. Moreover, cytotoxic
drugs can promote antitumor immune responses by alter-
ing the tumor-induced tolerogenic mechanisms occurring
within the tumor microenvironment [42].
Herein, we investigated in a phase I clinical trial a
chemo-immunotherapy combination approach based on
IFN-DCs injected into metastatic tumor lesions of patients
with advanced melanoma pre-treated one day before with
DTIC, with the aim of triggering a strong and long-lasting
immune response against melanoma antigens released in
situ, as a consequence of the chemotherapy-induced
cell death, and possibly taken up by the locally injected
IFN-DCs.
Materials and methods
Study design, patient selection and treatment
This was a phase I clinical trial, approved by the Ethical
Committees of Istituto Dermopatico dell’Immacolata (IDI)
of Rome and conducted according to Good Clinical
Practice and Declaration of Helsinki principles. Subjects
were included in the study only after having given their
written, informed consent and having carried out all the
procedures for complying inclusion/exclusion criteria.
Main criteria for eligibility included histologically con-
firmed malignant stage IV melanoma not suitable for
locoregional therapies with unresectable lesions and
suitable for chemotherapy; ECOG performance status of
0–1, adequate blood cell counts and kidney-liver func-
tion, written informed consent. Patients were excluded
if they had a concomitant or previous history of malignant
diseases, severe cardiovascular disease, clinically active in-
fections and/or significant autoimmune diseases.
Once enrolled, each patient underwent leukapheresis
to provide PBMCs from which autologous IFN-DCs
were prepared. Primary end-points were safety and toler-
ability of the treatment as well as the antitumor T-cell
responses. Secondary endpoint was the determination of
response rates and survival. Safety and tolerability of thetreatment were assessed by determining frequency, type,
and intensity of adverse events as well as the patient
compliance. T cell responses were assessed by determin-
ing magnitude and quality of peripheral tumor-specific
CD8+ T cell response. The clinical response was evalu-
ated by determining time to progression (TTP) and ob-
jective response (OR), according to RECIST/modified
WHO criteria. Before, during, and after treatment, blood
samples and tumor biopsies were drawn for determining
safety as well as potential efficacy parameters. During
treatment, patient clinical status was monitored at each
visit and any disease progression was checked by appro-
priate diagnostic investigations at specific time points.
Patients showing disease progression during the treatment
period were withdrawn from the study and considered not
assessable for analysis.
GMP preparation of IFN-DCs
Leukapheresis was performed by a Fresenius Com-Tech
blood cell separator (Fresenius Kabi, Friedberg, Germany)
using the White Blood Cell Set (P1YA) for the collection
of mononuclear cell (MNC) products. Monocytes enrich-
ment from aphaeresis was performed according to Elutra®
Cell Separation System Monocytes Enrichment Protocol.
The monocyte enriched fraction was analysed for cell
viability and cell counts and purity were assessed by flow
cytometry using CD14 mAb associated with the pan
leukocyte CD45 mAb (all from BD Biosciences, San Jose,
CA). When the purity of monocytes was less than 60%, an
additional step of separation, by centrifugation on an isos-
motic medium with a density of 1.077 g/ml as a Lympho-
prep™ (Axis-Shield, Oslo, Norway), was performed. The
enriched monocytes were cultured for three days in bags
(Afc/American Fluoroseal Corporation, Gaithersburg, MD)
at the concentration of 2×106 cells/ml in a culture medium
(CellGenix GmbH, Freiburg, Germany) containing GM-
CSF (600 IU/ml) (Leukine sargramostim, Bayer Healthcare
Pharmaceuticals, Seattle, WA) and IFN-α2b (10,000 IU/ml)
(Merck Sharp & Dohme Limited, Hoddesdon, UK).
IFN-DCs were then harvested, counted and re-
suspended in freezing medium, prepared by mixing 9
volumes of 5% Human Serum Albumin (HSA) (Baxter
S.p.A., Rome, Italy) + 1 volume of DMSO (WAK-Chemie
Medical GmbH, Steinbach, Germany), at the final con-
centration of 1-2×107 cells/ml. Aliquots of 0.5 ml cell
suspension were transferred to 2 ml cryo-vials, that were
deep-frozen under decreasing controlled temperature
conditions and stored in liquid nitrogen vapor phase.
Characterization of IFN-DCs
Cell count, viability and recovery were evaluated by using
trypan blue staining, counted into at least two large differ-
ent squares of the Neubauer chamber. The viability was
calculated as viable Cell Density × 100/total Cell Density.
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number of thawed viable IFN-DCs over the number of
frozen viable IFN-DCs. Sterility was determined by
Direct Inoculation technique and endotoxin status was
evaluated by the LAL test. Immunophenotype of IFN-
DCs was analyzed by flow cytometry using a panel of
antibodies specific for HLA-ABC, HLA-DR, CD45,
CD11c, CD1a, CD86, CD83, CD80, CD40 and CD14
(all from BD Biosciences, San Jose, CA). The capability
of IFN-DCs to phagocytize antigens was verified by
flow cytometry using OVA conjugated with fluorescein
(OVA-FITC) (Molecular Probes, Inc., Eugene, OR).
Flow cytometry was carried out with a FACSCanto
flow cytometer and the data were analyzed using the
FACSDiva software (BD Bioscience, San Jose, CA).
IFN-DCs release criteria were: cell viability >70%, cell
recovery >50%, antigen uptake >30%, CD80+ >80%,
CD86+ >50%, CD83+ >10%, HLA-DR+ > 80%, HLA-
ABC+ >80%, CD14+ <65%, CD14 MFI <1000.
Gene expression profiling
Total RNA was isolated from at least 5 million cells
using RNeasy kit (Qiagen, Valencia, CA, USA) for both
monocytes and IFN-DCs before and after cryopreserva-
tion/thawing. After passing quality control assessment of
integrity of purity analyzed with ND-1000 Spectropho-
tometer (NanoDrop Technologies, Wilmington, DE, USA)
and Agilent 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany), RNA was amplified and labeled
using Agilent Low Input Quick-Amp Labeling Kit, one
color (Agilent Technologies) in the presence of cyanine
3-CTP according to manufacturer’s instructions and
hybridized on Agilent Chip (SurePrint G3 Human GE
8×60K Microarray) at 65°C for 17 hours. At the end of
the hybridization, chips were washed following manufac-
turer’s instructions and scanned on SureScan Microarray
Scanner (Agilent) and images analyzed using Agilent
Feature Extraction Software. Data were then analyzed
with BRB Array Tools (http://linus.nci.nih.gov/BRB-
ArrayTools.html ). The processed data set was subjected
to filtration based on signal intensity, spot quality and
presence across the data set.
Unsupervised hierarchical clustering was performed
using centered correlation and average linkage on aver-
age corrected values. Paired statistical analysis of genes
differentially expressed between IFN-DCs and mono-
cytes was performed on BRB using Random Variance
Model to increase accuracy of variance estimation across
the data set. False Discovery Rate was calculated as the
proportion of expected false positive observations on
total significant observations as described by Sorić
[43]. Gene Ontology (GO) analysis was performed on
genes statistically differentially expressed (p-value < 0.001)
showing a ratio on expression level IFN-DCs/monocytesgreater than 3 using the Database for Annotation,
Visualization and Integrated Discovery (DAVID, http://
david.abcc.ncifcrf.gov ) [44].
Detection of antigen-responsive T cells
Before, during and after completion of the therapy
blood samples from treated patients were collected in
lithium-heparin BD Vacutainer® vials (Becton, Dickinson
and Company, Franklin Lakes, NJ). Peripheral blood was
diluted 1:2 in PBS and stratified on LymphoprepTM
(Axis-Shield PoC AS, Oslo, Norway for Fresenius
KabiNorge AS). PBMCs obtained after density gradient
centrifugation were frozen at −80°C and stored in li-
quid nitrogen until testing.
T cell responses against melanoma associated antigens
(Melan-A/MART-1, NY-ESO-1, MAGE-A1, MAGE-A3,
gp100, Tyrosinase, Survivin) were assessed by prolifera-
tion assays by using protein-spanning of overlapping
peptides (PepMix™, JPT Peptide Technologies GmbH,
Berlin, Germany). Two PepMix™ Peptide Pools (HCMVA
(pp65) and actin), SEB (Sigma-Aldrich, St. Louis, MO),
and PPD (Staten Serum Institute, Copenhagen, DK,
Danish public Institution) were used as controls. Briefly,
2 × 105 PBMCs were cultured in triplicate in CellGro®
medium (CellGenix GmbH,Freiburg, Germany) supple-
mented with 1% penicillin-streptomycin in 96-well flat-
bottom trays (Corning Costar®, Tewksbury, MA) in the
presence of a single antigen-specific peptide pool (1
ug/ml). Cell cultures were conducted for 7 days and
[methyl-3H]thymidine (specific activity, 5 Ci/mmol;
Hartmann Analytic GmbH, Braunschweig, Germany)
was added at a final concentration of 0.5 μCi/well 18 h
before harvesting. DNA synthesis was evaluated by
counting [methyl-3H]thymidine incorporation with a
TriluxMicrobeta counter (Perkin-Elmer, Waltham, MA).
Stimulation index (SI) was calculated as the ratio between
counts per min (cpm) of the antigen-stimulated lympho-
cyte culture and mean cpm of cultures stimulated with
actin or two non-activating peptide pools or unstimulated.
Proliferative response was considered positive when SI
was ≥ 2. Samples from the same patient were analyzed
simultaneously.
Tumor specific T cell lines and intracellular staining
Tumor specific T cell lines were generated by in vitro
stimulation of cryopreserved PBMCs isolated at baseline
and post-therapy time points. Briefly, cells were thawed,
counted and cultured for 12 days in the presence of IL-2
and IL-7 (added every 2/3 days during the culture) and
with the above mentioned peptides pools (1 μg/ml). Half
dose of each peptide pool was added at day 7 of culture.
IL-2 was removed from the medium 3 days before test
(i.e., day 9). On day 12 cells were harvested and assessed
for CD69 expression (activation) and for the production
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ously described [45]. Before ICS, each sample of in vitro
expanded cells was labelled with HLA-A2*0201 peptide
phycoerythrin (PE) multimer complexes specific for
Melan-A/MART-1, NY-ESO-1, Tyrosinase, gp100 (see
above), then washed and cultured at a 4:1 ratio with au-
tologous IFN-DCs pulsed or not with the peptide pools
(1 ug/ml) for 1 hour at 37°C. After the addition of bre-
feldin A (Golgi Plug) and monensin (Golgi stop) (Becton
Dickinson, San Jose, CA, USA), cells were incubated for
additional 5 hours. Following the 6 hour stimulation
time, final 2 mM EDTA was added to each well and in-
cubated for 15 min. Cells were then incubated for
30 min at 4°C with a 50 μl antibody cocktail containing
the surface antigens anti-CD3 APC H7, anti-CD4 Alexa
Fluor 488, anti-CD8 Alexa Fluor 647, anti-CD69 PERCP
CY5.5 (BD Biosciences). After surface staining cells were
fixed/permeabilized with the BD intrasure kit reagents
(BD Biosciences) according to the manufacturer’s intruc-
tions in order to enable intracellular staining with anti-
interferon-gamma (IFN-γ) PE CY7 (BD Biosciences).
Cells were then washed, resuspended in paraformalde-
hyde 2%, acquired on a FACSCanto flow cytometer in-
strument (BD Biosciences) and analyzed by FACSDiva
and/or FlowJo software, version 10 (Tree Star, Ashland).
Negative control included cells cocultured with unpulsed
IFN-DCs, while Staphylococcus enterotoxin B (SEB;
Sigma-Aldrich, Munich, Germany, used at 2 μg/mL)
was used as positive control.
Cytokine assays
Supernatants of lymphoproliferation cultures were col-
lected at day 6, just before adding [methyl-3H]thymidine,
immediately frozen at −20°C and, once thawed, assayed in
the same plate by Bio-Plex® Multiplex System, Bio-Rad
Laboratories, Inc. (Hercules, CA). Assay was performed
by a custom kit for simultaneous detection of: IL-1β, IL-2,
IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-γ, TNF-α and
GM-CSF and by a kit for IFN-α.
Immunofluorescence and confocal microscopy
Immunofluorescent labeling was performed on Formalin
Fixed Paraffin Embedded (IF-FFPE) tissue sections.
Slides (5 μm thick) were deparaffinized, hydrated through
graded alcohols and subjected to a Heat-induced Epitope
Retrieval step by citrate buffer pH 6,0 (Novus Biologicals)
for 3×3 min in microwave. Sections were washed with
PBS-T and blocked in PBS-BSA 3% for 30 min at 37°C.
Primary antibody (rabbit anti-human CD45, Abcam;
mouse anti-human CD45RO, Dako; rabbit anti-human
CD68, Abbiotec) was added in PBS-BSA 3% and incu-
bated at 37°C for 30 min. After washing, sections were
incubated for 30 min at 37°C with secondary anti-
bodies (AlexaFluor 594 goat anti-rabbit MolecularProbes; AlexaFluor 488 goat anti-mouse; Invitrogen)
plus DAPI. Sections were mounted in Vectashield anti-
fade medium (Vector Laboratories) and fluorescence
images were taken by Leica confocal microscope.
Results
Trial design and patient characteristics
The study was designed to assess toxicity and immuno-
genicity of a DC-based immunotherapy associated with
standard chemotherapy. From July 2011 to March 2013,
ten patients with confirmed diagnosis of metastatic mel-
anoma [46] were screened for their compliance to the
study inclusion/exclusion criteria and six of them were
enrolled (Table 1). With the exception of one patient
presenting unresectable stage IIIC melanoma, all the
others were stage IV. Age of patients ranged between 38
and 73 and three of the six were females. Treatment
regimen consisted of six administrations of DTIC
(1000 mg/m2 i.v. every 3 weeks) each followed one day
later by intratumoral injection of ten million unloaded
autologous IFN-DCs according to the schedule illus-
trated in Figure 1. Three out of the six patients com-
pleted the treatment (DTIC + injections of DCs) and
were assessed for immune and clinical responses, while
three patients were excluded because of a rapid disease
progression (two patients received two injections of
DCs and one progressed before the first vaccination).
Four out of five enrolled patients received previous
treatments, including immune checkpoint and/or BRAF
inhibitors. Patients’ characteristics are listed in Table 1.
Phenotypic and molecular features of IFN-DCs used in the
clinical trial
Monocyte-derived IFN-DCs generated from each patient
were characterized according to release criteria (see
Materials and Methods) for cell viability, cell counts, cell
phenotype and antigen uptake on cryopreserved ali-
quots. As shown in Figure 2a and b, IFN-DCs generated
for the 5 patients met all release criteria. In fact, viability
ranged between 73% and 91% (release threshold 70%);
cell recovery was in the range of 55-90% (release thresh-
old 50%); and phagocytic activity averaged in the range
of 40-50% with IFN-DCs of patient 3 showing approxi-
mately 70% (release threshold 30%).
Phenotypic analysis showed that IFN-DCs from all pa-
tients displayed significant expression of class I and class
II molecules, co-stimulatory receptors CD80 /CD86 and
CD11c marker. IFN-DCs also retained CD14 expression
at the same level among different patients, but showed
more variable levels of CD83, CD1a and CD40 (Figure 2b).
Then, to more deeply characterize our cell products
and monitor molecular changes occurring during the
manufacturing process, we also analyzed gene expression
profiles of starting monocytes, of DCs at the end of the
Table 1 Patient characteristics and clinical outcomes








1 F 71 IIIC Skin recurrence None Yes Complete SD 7 34
2 F 47 IV Lung, lymphonodal 2 (DTIC, Vemurafenib) Yes 2 injections PD 2 2
3 M 73 IV Skin lymphnodal, liver 3 (DTIC, Vemurafenib,
Ipilimumab)
Yes Complete SD 26 31
4 M 38 IV Lymphonodal, lung 1(Vemurafenib) Yes 2 injections PD 2 5
5 M 66 IV Lung, lymphonodal 3 (DTIC-IL2, BOLD,
Ipilimumab)
Yes Complete SD 5 9
6 F 68 IV Skin, lung, lymphonodal 2 (DTIC, Ipilimumab Yes No injection NA NA NA
7 F 63 IV Adrenal, lymphonodal none No
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the thawed DCs product from each of the five patients
for which DCs were manufactured. As shown in
Figure 3a, unsupervised clustering of the whole dataset
clearly separated monocytes from DCs, showing that a
huge change occurred during differentiation of mono-
cytes into IFN-DCs. Also, DCs clustered according to
patient, implying that changes occurring along cryo-
preservation and subsequent thawing of the cells are
little compared to inter-patient differences and insig-
nificant when considering changes occurring during
DC differentiation, which was the main focus of our
microarray analysis.
Therefore, to better characterize molecular pathways
affected during IFN-DC differentiation, we performed a
paired class comparison between monocytes and IFN-
DCs and observed that 5,725 genes were differentially
expressed with a p-value < 0.001 (false discovery rate <
0.01) (Figure 3b and Table 2). As expected, among top
up-regulated genes there were many well-known IFN-
α-induced ones, such as ISG15, MX1, IFI27 and IFIT1.
Interestingly, several chemokines, such as chemokine
(C-C motif ) ligand 13 (CCL13), CCL17 and CCL19,Figure 1 Schedule of treatment regimen and blood samples for safety and
months (m). Pre: pre-treatment time point.were all strongly up-regulated showing fold changes
above 100, suggesting a strong chemotactic potential
of IFN-DCs towards T cells and other immune cells.
Then, to classify genes induced by IFN-DC differen-
tiation, we performed gene ontology (GO) analysis
on genes up-regulated in IFN-DCs compared to
monocytes, focusing on mostly modulated genes (fold
change >3) (Figure 2c). Most over-represented families
were immune related with a strong up-regulation of
genes belonging to “antigen processing and presenta-
tion” and “response to virus”. Considered the relevance
of these GO families, we looked at exactly which genes
were in our analysis falling into these families. Up-
regulated “antigen processing and presentation” genes
were mainly class II HLA genes and CD1 genes (a, b, c,
and e), highlighting the well-documented ability of
IFN-DCs to strongly process and present antigens.
Altogether, these data indicated that strong molecular
changes are induced upon monocyte differentiation
into IFN-DCs and that GMP-manufactured IFN-DCs
were empowered, at least at gene expression level, with
strong chemotactic and antigen processing and presen-
tation abilities.efficacy endpoints evaluation. T: time point expressed as days or
Figure 2 Characterization of the patients’ IFN-DCs used in the clinical trial. IFN-DCs were checked for viability and recovery and capability of
antigen uptake(a), and characterized for typical differentiation and activation markers (b) as well as class I-II and costimulation molecules (c).
Rozera et al. Journal of Translational Medicine  (2015) 13:139 Page 7 of 13Evalutation of toxicity of the IFN-DCs/DITC regimen and
clinical outcome
No severe side effects (Grade III/IV, National Cancer
Institute Common Toxicity Criteria version 4) were ob-
served. Grade I toxicity resulted in pain in the site of
DC injection, lasting less than 30 min. After the comple-
tion of the programmed therapy, patients 1 and 3 devel-
oped signs of autoimmunity (vitiligo). Clinical response
was not a primary end point of the current study.
Although no major responses were observed, all three
patients experienced disease stabilization (7, 26 and
5 months for patients 1, 3, and 5, respectively). After
progression, patient 1 underwent amputation of the an-
terior part of the foot where melanoma lesion pro-
gressed and she is still alive (OS 34 months). Patient 3
progressed after 26 months and is currently alive and be-
ing treated with Pembrolizumab 2 mg/Kg every 3 weeks,
into an expanded access program (OS 31 months).
Characterization of the immune response
The immunological monitoring was focused on assessing
whether the administration of IFN-DCs could result in
activation of tumor-specific T cells. Considering that the
DCs used were injected intratumorally with the aim of
in situ taking up antigen of DTIC-induced apoptotic
tumor cells, we decided to test reactivity of T cellsagainst a broad range of well-known melanoma associ-
ated antigens (i.e., MART-1, NY-ESO-1, MAGE-A1,
MAGE-A3, gp100, tyrosinase and survivin). Thus, we set
up a lymphoproliferation assay by culturing patient’s
PBMCs, collected before and at different times after
treatment, in the presence of overlapping peptide pools,
each related to a specific melanoma-associated antigen
and spanning the whole protein sequence. We carried
out the analysis on the 3 patients that completed the
planned DC-based regimen. As depicted in Figure 4a,
patient 1 showed lymphoproliferative response to tyro-
sinase, gp100 and NY-ESO-1 usually occurring at times
after treatment (i.e., 8 or 11 months). Patient 3 showed a
response to gp100 already on prevaccination sample, but
did exhibit the induction of a lymphoproliferative re-
sponse against tyrosinase and an increase against gp100
at 8 months. Responses against tyrosinase, gp100 and
MAGE-A1 (not shown) were already present in Patient
5 in prevaccination samples and remained unaltered for
tyrosinase, while it was markedly reduced for gp100 after
treatment. We were unable to detect any response be-
fore and post-treatment towards MART-1, MAGE-A3
and survivin (data not shown).
In order to expand the response to these tumor anti-
gens, we performed an in vitro sensitization of patient’s
PBMCs with those peptide pools showing response in
Figure 3 Gene expression analysis of IFN-DCs. a. Unsupervised Hierarchical Clustering of samples using the whole dataset. Monocyte, IFN-DCs
and prior to cryopreservation DCs are shown by red, green and blue bars, respectively; b) Heatmap of the average corrected expression levels of
the 5725 genes differentially expressed between IFN-DCs and monocytes with a p-value < 0.001. Genes are in rows and samples in columns. Monocyte,
IFN-DCs and prior to cryopreservation DCs are shown by red, green and blue bars, respectively; c) Gene Ontology Analysis of up-regulated genes in
IFN-DCs vs monocytes (p-value < 0.001 and ratio >3). The plot show for each GO “biological function” term the enrichment among genes up-regulated
in IFN-DCs expressed as –log10(p-value). Enrichment p-values were calculated through hypergeometric test. Statistical significance threshold for
hypergeometric test was set to 0.05 (i.e., −log10(p-value) > 1.3 were statistically significant).
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city, frequency and effector function of T cells after
in vitro sensitization. As shown in Figure 4b, cells from
both patient 1 and 3, although at different levels, showed
an increase in the percentage of CD8+ cells producing
IFN-γ in response to both tyrosinase and NY-ESO-1
compared to prevaccination levels , while cells from
patient 5 did not show any increase to these antigens.
Similar conclusions can be traced on levels of CD69
expression (data not shown). Of note, a strong produc-
tion of IFN-γ in response to NY-ESO-1 (especially in
CD3+CD4+-gated cells) was already present in patient
5 before treatment with IFN-DCs and was maintained
at 8 months. Further analysis performed by multimerstaining specific for some tumor antigens, revealed
that patient 1 showed no increase of multimer+ cells
overtime (data not shown). In patient 3, the proportions
of CD8+Tyrosinase+ e CD8+MART-1+ cells were transi-
ently expanded. In patient 5, the analysis indicated an
higher percentage of NY-ESO-1 specific tetramer+ cells
over time (data not shown).
It is worth noting that, among the treated patients, pa-
tient 3 showed an overall good immune response to
some relevant tumor peptides (Figure 4a and b) as well
as a durable disease stabilization (Table 1). Approxi-
mately 21 months after enrolment, patient 3 underwent
disease evaluation by PET/CT scanning, confirming the
status of disease stabilization. Therefore, we took the
Table 2 20 most up-regulated genes in IFN-DCs vs
monocytes
Symbol Name IFN-DCs /mono
expression level
CCL17 chemokine (C-C motif) ligand 17 10480.71




GGT5 gamma-glutamyltransferase 5 409.08






CCL19 chemokine (C-C motif) ligand 19 144.92
IFITM1 interferon induced transmembrane
protein 1
139.12




CCL13 chemokine (C-C motif) ligand 13 123.96
ISG15 ISG15 ubiquitin-like modifier 114.72
IFI6 interferon, alpha-inducible protein 6 105.97
CLEC10A C-type lectin domain family 10,
member A
100.71
LAD1 ladinin 1 99.93




NUP62 nucleoporin 62 kDa 80.03




RNASE1 ribonuclease, RNase A family, 1
(pancreatic)
73.2
RASAL1 RAS protein activator like 1
(GAP1 like)
70.97
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and the lymph node biopsies. As illustrated in Figure 5a,
PBMC from patient 3 retained at this time point a lym-
phoproliferative response to tyrosinase, while the re-
sponse to gp100 was reduced to pre-vaccination levels
and the one to NY-ESO-1 remained stable. We also
assessed T cell activity and effector function by measur-
ing production of several cytokines in the same cultures
used for the lymphoproliferation assay. As shown in
Figure 5b, we found appreciable amounts of the inflam-
matory cytokines IFN-γ, IL-1β, IL-6 and IL-8 in cultures
stimulated by tyrosinase and NY-ESO-1, while no cyto-
kines were detectable in other peptide-specific cultures
(data not shown). Levels of other cytokines (i.e., IL-2, IL-4,
IL-10, IL-12, IL-17A, TNF-α and GM-CSF) did not reach
minimum detection threshold in any of the antigen-
specific cultures. In addition to this, we analyzed immunecell infiltrates in tumor tissues collected at this point from
patient 3. As shown in Figure 5c, abundant tumor infil-
trating lymphocytes were present (left panel), which were
characterized by memory phenotype (central panel). Also,
a large number of monocytes/macrophages was present
(right panel).
Discussion
Here, we report the results of a phase I clinical study
evaluating a new chemo-immunotherapy approach based
on intratumoral injection of unloaded IFN-DCs one day
after DTIC in patients with advanced melanoma. The ra-
tionale was to combine tumor cell death induced by the
chemotherapeutic agent with the phagocytic activity and
T-cell stimulatory properties of IFN-DCs, therefore aim-
ing at an in vivo loading of DCs with patient specific
tumor associated antigens. The chemo-immunotherapy
was well tolerated and the induction of antigen specific
immune responses was observed in two out of the three
patients that completed the protocol treatment. In par-
ticular, one patient was revaluated at 21 months and anti-
gen specific immune response was still detectable and
proved to be associated with high infiltration of immune
cells inside the tumor lesion.
Intratumoral injection of DCs combined with tumor cell
death inducing agents or therapies has already been tested
and proved effective in animal models [32,36,37,47-49].
Also, clinical studies have been performed combining DCs
with radiotherapy or monoclonal antibody in some clinical
settings showing safety and feasibility of the approach
[33,38,39,50,51]. Our study is the first showing safety and
feasibility of IFN-DCs injected intratumorally one day
after DTIC. IFN-DCs have been widely characterized
in vitro and in animal models for their peculiar phenotype
and functional properties [12,14-16]. In this study, we
characterized the gene expression profiling of monocytes
and IFN-DC from patients, showing that during DC dif-
ferentiation/maturation process IFN affects significantly
mainly genes involved in antigen processing and presenta-
tion as well as activation of immune responses, in agree-
ment with previous findings [12,14]. Our results also
confirmed the partially mature phenotype of these cells as
well as their strong phagocytic and chemotactic activity.
All these features may have played a key role in our setting
by overcoming tumor microenvironment immunosup-
pressive signals [52-54] while maintaining the necessary
high phagocytic activity instrumental for processing anti-
gens released by apoptotic tumor cells. In line with all the
published results from clinical studies based on standard
IL-4-conditioned DCs, also IFN-DCs were well tolerated
and only grade I toxicity was observed in treated patients.
On the other hand, also DTIC may have played a key role
in our setting. In fact, recent studies have shown its im-
munogenic properties, mainly triggering or enhancing the
Figure 4 Characterization of immune responses of patients that completed the treatment. a. Lymphoproliferation assay of PBMCs collected at
indicated time points and stimulated with different melanoma-associated antigens (NY-ESO-1, tyrosinase, gp100, MART-1, survivin, MAGE-A1, and
MAGE-A3). Proliferative activity was reported only for antigen-positive culture. Pre: prevaccination time; m: months. b. Intracellular cytokine
staining (ICS) performed on T cell lines derived from in vitro expansion of PBMCs collected at different time points during treatment, with the
tyrosinase, NY-ESO-1 and gp100 peptide pools. Histograms represent percentages of IFN-γ positive cells assessed within the CD3 + CD8+ gate
after 6 h stimulation with IFN-DCs pulsed with the indicated peptides pools. Unpulsed IFN-DC were used as a control at each time point and for
each antigen resulting in almost undetectable or very low levels of IFN-γ positive cells (% ranging from 0.02 to 0.08) for all samples, except in the
case of both NY-ESO-1-specific samples (0.2%) from Pt5. Cells were analyzed by flow cytometry using a FACS DIVA and FlowJo software (version
10; TreeStar).
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moting NK-cell cytotoxicity and IFN-γ-dependent
tumor specific T cell activation [55]. These observa-
tions, together with the evidences of clinical and im-
munological response observed in the three treated
patients warrant future clinical studies to evaluate efficacy
of this chemo-immunotherapy and better characterize its
mechanism of action.
The analysis of immunological response of patients to
tumor antigens is critical for correct evaluation of the ef-
ficacy of chemo-immunotherapeutic approach. However,
differently from pulsed-DC-based settings, where testing
reactivity against pulsed antigens is relatively easy, in the
setting of in situ loading the antigens processed and pre-
sented by DCs are unknown. Here, by testing a broad
range of well-known melanoma associated antigens, we
had evidences of immunological activation against tyrosin-
ase, gp100 and NY-ESO-1 in the two patients showing
long-term stable disease. It is also noteworthy to mentionthat both these patients also experienced vitiligo. Vitiligo
is an autoimmune condition due to immune-dependent
destruction of melanocytes; and development of vitiligo in
melanoma treated patients has a good prognostic value
[56,57]. The exact mechanisms of melanoma-associated
vitiligo development are still under study, but it is clear
that CD8+ T cell recognizing autoantigens have a major
role [58] and that tyrosinase and gp100 are among these
autoantigens [59]. Strength and relevance of this associ-
ation (i.e., induction of T cell response against tyrosinase
and gp100 and development of vitiligo) in our setting will
be evaluated more in details in future studies with larger
cohorts of patients.
Evaluation of clinical efficacy was not among the
study endpoints. However, we did observe long-term
disease stabilization in patient 3. The patient was en-
rolled after progressing from three different thera-
peutic approach: standard DTIC, Vemurafenib and
Ipilimumab. At time of this writing, the patient is still
Figure 5 Long term immune responses of patient 3 showing durable disease stabilitazion. a. Lymphoproliferation assay in response to antigen
stimulation of PBMCs from pt3 collected at T21m, compared with results obtained from the previous tests. b. Lymphocyte cultures (the same as
in panel a) analyzed for cytokine production by Bio-Plex® Multiplex System. Only cytokine-positive antigen-specific cultures are shown. Negative
controls showed no detectable cytokine levels except for IL-8-specific samples (2.6 × 103 pg/ml and 3 × 103 pg/ml for, respectively, time points
T0 and T21). c. Immunofluorescence of biopsy from pt3 metastatic lesion. The tumor sample was collected 1 month after the last evaluation of
patient clinical status by PET (T21m). The immunofluorescence microscopy was done using antibodies specific for CD45, CD45RO, and CD68
stained with 4′,6-diamidino-2-phenylindole (DAPI). Images show that tumor lesion is abundantly infiltrated both by T lymphocytes (a) which are
characterized by a memory phenotype (b) and a monocyte/macrophage population (c).
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in particular, after 26 months of disease stabilization,
due to disease progression he started therapy with
Pembrolizumab as part of an expanded access pro-
gram. Whether previous therapies had a role in this re-
sponse is impossible to evaluate. Kinetics of responsewith Ipilimumab after initial progression have been de-
scribed, usually occurring few months after treatment
[60,61]. The patient was treated with ipilimumab 6 months
before enrolment and showed disease progression
(lymphonodal and lung) by modified WHO criteria
after 26 months [62].
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In conclusion, here we report the results of a phase I
clinical study testing a chemo-immunotherapeutic ap-
proach based on IFN-DCs injected intratumorally one
day after DTIC in advanced melanoma. The treatment
was well tolerated, and clinical and immunological
responses, including development of vitiligo, were ob-
served, therefore warranting additional clinical studies
aimed at evaluating efficacy of this approach. Other
than hold promises for this setting, this approach
should also be evaluated for other solid tumors by
selecting strong immunogenic cell death agents to be
combined with patient-derived IFN-DCs.
Abbreviation
DTIC: Dacarbazine; DCs: Dendritic Cells; IFN: Interferon; NK: Natural Killer;
Th-1: T-helper-1; TLRs: Toll-like Receptors.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ImC designed the study, analyzed the data and drafted the manuscript; CR
was involved in GMP preparation and control of cell drugs and in drafting
the manuscript; GD, LS, EM, DM, DC, MN, PR, were involved in GMP
preparation and control of cell drugs; GAC, IdC, AP, PM were involved in
clinical management of patients and provided patient’s material and gave
critical comments on the manuscript; LC, EA performed molecular
characterization of cell drugs and LC drafted the manuscript; FU, IM, CB, RB,
developed and carried out immune monitoring; PS performed
immunofluorescence assay; FM, EP gave critical comments and edited the
manuscript, FB supervised all phases of the study, gave critical comments
and edited the manuscript. All authors read, reviewed and approved the
final manuscript.
Acknowledgements
This study was funded in part by grants from the Italian Ministry of Health
(Ricerca Finalizzata) and from the Italian Association for Cancer Research. We
would like to gratefully thank Dr. Belinda Palermo and Cosmo Di Donna for
assistance and technical support with the immunomonitoring assays, and
Serena Cecchetti, for help and assistance with immunofluorescence and
confocal microscopy. We would also like to thank Cinzia Berdini for
assistance with leukapheresis procedure and Teodoro Squatriti, Rosina
Bellizzi, Fabiola Diamanti and Daniela Diamanti for technical assistance.
Author details
1Department of Hematology, Oncology and Molecular Medicine, Istituto
Superiore di Sanità, viale Regina Elena 299, Rome 00161, Italy. 2IV
Dermatology Oncology Unit, Istituto Dermopatico dell’Immacolata, Istituto di
Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), via Monti Creta 104, Rome
00167, Italy. 3Immunohematology and Transfusion Medicine Unit, Sapienza
University of Rome, Sant’Andrea Hospital, via di Grottarossa 1035, Rome
00189, Italy. 4National AIDS Center, Istituto Superiore di Sanità, viale Regina
Elena 299, Rome 00161, Italy. 5Department of Oncology, Sapienza University
of Rome, Sant’Andrea Hospital, via di Grottarossa 1035, Rome 00189, Italy.
Received: 18 November 2014 Accepted: 23 March 2015
References
1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR,
et al. Final version of 2009 AJCC melanoma staging and classification. J Clin
Oncol. 2009;27:6199–206.
2. Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in
metastatic melanoma: what have we learned in 30 years? Eur J Cancer.
2004;40:1825–36.3. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic
review of medical treatment in melanoma: current status and future
prospects. Oncologist. 2011;16:5–24.
4. Eggermont AMM. Advances in systemic treatment of melanoma. Ann
Oncol. 2010;21 Suppl 7:vii339–44.
5. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant
melanoma? Lancet Oncol. 2013;14:e60–9.
6. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al.
Improved survival with Ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010;363:711–23.
7. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al.
Pooled analysis of long-term survival data from phase II and phase III trials
of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015.
[Epub ahead of print].
8. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al.
Development of ipilimumab: a novel immunotherapeutic approach for the
treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1–13.
9. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines.
Immunity. 2013;39:38–48.
10. Engell-Noerregaard L. Review of clinical studies on dendritic cell-based
vaccination of patients with malignant melanoma: assessment of correlation
between clinical response and vaccine. Cancer Immunol. 2009;58:1–14.
11. Pizzurro GA, Barrio MM. Dendritic cell-based vaccine efficacy: aiming for hot
spots. Front Immunol. 2015;6:91. eCollection 2015.
12. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, et al.
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell
development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med.
2000;191:1777–88.
13. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, et al.
Interferon-alpha and granulocyte-macrophage colony-stimulating factor
differentiate peripheral blood monocytes into potent antigen-presenting
cells. J Leukoc Biol. 1998;64:358–67.
14. Santini SM, Lapenta C, Santodonato L, D’Agostino G, Belardelli F, Ferrantini
M. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Handb Exp Pharmacol. 2009;188:295–317.
15. Farkas A, Tonel G, Nestle FO. Interferon-alpha and viral triggers promote
functional maturation of human monocyte-derived dendritic cells. Br J
Dermatol. 2008;158:921–9.
16. Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, et al. IFN-alpha
skews monocytes into CD56 + −expressing dendritic cells with potent
functional activities in vitro and in vivo. J Immunol. 2008;180:1462–70.
17. Parlato S, Romagnoli G, Spadaro F, Canini I, Sirabella P, Borghi P, et al. LOX-1
as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen
presentation in dendritic cells. Blood. 2010;115:1554–63.
18. Santodonato L, D’Agostino G, Nisini R, Mariotti S, Monque DM, Spada M,
et al. Monocyte-derived dendritic cells generated after a short-term culture
with IFN-alpha and granulocyte-macrophage colony-stimulating factor
stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
J Immunol. 2003;170:5195–202.
19. Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, et al. Role of cross-talk
between IFN-alpha-induced monocyte-derived dendritic cells and NK cells
in priming CD8+ T cell responses against human tumor antigens.
J Immunol. 2004;172:5363–70.
20. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, et al.
IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-
priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol.
2006;36:2046–60.
21. Santini SM, Lapenta C, Donati S, Spadaro F, Belardelli F, Ferrantini M.
Interferon-α-conditioned human monocytes combine a Th-1-orienting
attitude with the induction of autologous Th-17 responses: role of IL-23 and
IL-12. PLoS One. 2011;6:e17364.
22. Bracci L, Schumacher R, Provenzano M, Adamina M, Rosenthal R, Groeper C,
et al. Efficient stimulation of T cell responses by human IFN-alpha-induced
dendritic cells does not require Toll-like receptor triggering. J Immunother.
2008;31:466–74.
23. Farkas A, Kemény L. Interferon-α in the generation of monocyte-derived
dendritic cells: recent advances and implications for dermatology. Br J
Dermatol. 2011;165:247–54.
24. Bracci L, Capone I, Moschella F, Proietti E, Belardelli F. Exploiting dendritic
cells in the development of cancer vaccines. Expert Rev Vaccines.
2013;12:1195–210.
Rozera et al. Journal of Translational Medicine  (2015) 13:139 Page 13 of 1325. Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG,
et al. Local administration of dendritic cells inhibits established breast tumor
growth: implications for apoptosis-inducing agents. Cancer Res.
2001;61:228–36.
26. Song W, Levy R. Therapeutic vaccination against murine lymphoma by
intratumoral injection of naive dendritic cells. Cancer Res. 2005;65:5958–64.
27. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral
injection of dendritic cells derived in vitro in patients with metastatic
cancer. Cancer. 2000;89:2646–54.
28. Mazzolini G, Alfaro C, Sangro B, Feijoó E, Ruiz J, Benito A, et al. Intratumoral
injection of dendritic cells engineered to secrete interleukin-12 by recombinant
adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol.
2005;23:999–1010.
29. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age.
Nature. 2011;480:480–9.
30. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone
marrow-derived dendritic cells and systemic chemotherapy to treat
pre-existing murine tumors. Cancer Res. 2001;61:7530–5.
31. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, et al.
Effective combination of chemotherapy and dendritic cell administration for
the treatment of advanced-stage experimental breast cancer. Clin Cancer
Res. 2003;9:285–94.
32. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, et al.
Intratumoral injection of dendritic cells after treatment of anticancer drugs
induces tumor-specific antitumor effect in vivo. Int J Cancer. 2002;101:265–9.
33. Mann DL, Celluzzi CM, Hankey KG, Harris KM, Watanabe R, Hasumi K.
Combining conventional therapies with intratumoral injection of
autologous dendritic cells and activated T cells to treat patients with
advanced cancers. Ann N Y Acad Sci. 2009;1174:41–50.
34. Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, et al.
Clinical trial of the intratumoral administration of labeled DC combined
with systemic chemotherapy for esophageal cancer. J Immunother.
2012;35:513–21.
35. Nikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic
cell administration induces a potent antitumor response in tumor-bearing
mice: approach to treatment of advanced stage cancer. Int J Cancer.
2001;94:825–33.
36. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, et al.
Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic
cell administration. Cancer Res. 2003;63:8466–75.
37. Akutsu Y, Matsubara H, Urashima T, Komatsu A, Sakata H, Nishimori T, et al.
Combination of direct intratumoral administration of dendritic cells and
irradiation induces strong systemic antitumor effect mediated by GRP94/
gp96 against squamous cell carcinoma in mice. Int J Oncol. 2007;31:509–15.
38. Hasumi K, Aoki Y, Wantanabe R, Mann DL. Clinical response of advanced
cancer patients to cellular immunotherapy and intensity-modulated
radiation therapy. Oncoimmunology. 2013;2:e26381.
39. Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, et al.
Combination of external beam radiotherapy (EBRT) with intratumoral
injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue
sarcoma patients. Int J Radiat Oncol Biol Phys. 2012;82:924–32.
40. Altvater B, Landmeier S, Pscherer S. 2B4 (CD244) signaling by recombinant
antigen-specific chimeric receptors costimulates natural killer cell activation
to leukemia and neuroblastoma cells. Clin Cancer. 2009;15:4857–66.
41. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of
conventional and targeted anticancer therapies: reinstating
immunosurveillance. Immunity. 2013;39:74–88.
42. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity.
Cancer Immunol Immunother. 2013;62:203–16.
43. Sorić B. Statistical “discoveries” and effect-size estimation. J Am Stat Assoc.
1989;84:608–10.
44. Huang DW, Sherman BT, Lempicki R a. Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc.
2009;4:44–57.
45. Macchia I, Urbani F, Proietti E. Immune monitoring in cancer vaccine clinical
trials: critical issues of functional flow cytometry-based assays. Biomed Res
Int. 2013;2013:726239.
46. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC
cancer staging manual. 7th ed. New York, NY: Springer; 2010.47. Kim K-W, Kim S-H, Shin J-G, Kim G-S, Son Y-O, Park S-W, et al. Direct
injection of immature dendritic cells into irradiated tumor induces efficient
antitumor immunity. Int J Cancer. 2004;109:685–90.
48. Lee T-H, Cho Y-H, Lee JD, Yang WI, Shin JL, Lee M-G. Enhanced antitumor
effect of dendritic cell based immunotherapy after intratumoral injection of
radionuclide Ho-166 against B16 melanoma. Immunol Lett. 2006;106:19–26.
49. Tanaka K, Ito A, Kobayashi T, Kawamura T, Shimada S, Matsumoto K, et al.
Intratumoral injection of immature dendritic cells enhances antitumor effect
of hyperthermia using magnetic nanoparticles. Int J Cancer. 2005;116:624–33.
50. Chi K-H, Liu S-J, Li C-P, Kuo H-P, Wang Y-S, Chao Y, et al. Combination of
conformal radiotherapy and intratumoral injection of adoptive dendritic cell
immunotherapy in refractory hepatoma. J Immunother. 2005;28:129–35.
51. Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, et al.
Sequential intranodal immunotherapy induces anti-tumor immunity and
correlated regression of disseminated follicular lymphoma. Blood.
2015;125:82–9.
52. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor
cells convert immature myeloid dendritic cells into TGF-beta-secreting cells
inducing CD4 + CD25+ regulatory T cell proliferation. J Exp Med.
2005;202:919–29.
53. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, et al.
Tumour tissue microenvironment can inhibit dendritic cell maturation in
colorectal cancer. PLoS One. 2011;6:e27944.
54. Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor
immunoenvironment. Cancer Immunol Immunother. 2012;61:223–30.
55. Hervieu A, Rébé C, Végran F, Chalmin F, Bruchard M, Vabres P, et al.
Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells
activates NK and CD8 T cells and restrains melanoma growth. J Invest
Dermatol. 2013;133:499–508.
56. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone
B, et al. Vitiligo is an independent favourable prognostic factor in stage III
and IV metastatic melanoma patients: results from a single-institution
hospital-based observational cohort study. Ann Oncol. 2010;21:409–14.
57. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB.
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am
Acad Dermatol. 1983;9:689–96.
58. Byrne KT, Turk MJ. New perspectives on the role of Vitiligo in immune
responses to melanoma ABSTRACT. Oncotarget. 2011;2:684–94.
59. Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, et al. HLA-A2
restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo
patients are related to disease activity and are predominantly directed
against MelanA/MART1. J Invest Dermatol. 2001;116:891–7.
60. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse
events and kinetics of response with ipilimumab. J Clin Oncol.
2012;30:2691–7.
61. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al.
The Society for Immunotherapy of Cancer consensus statement on tumour
immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin
Oncol. 2013;10:588–98.
62. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines
for the evaluation of immune therapy activity in solid tumors: immune-related
response criteria. Clin Cancer Res. 2009;15:7412–20.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
